126-18-1
中文名称
菝葜
英文名称
SMILAGENIN
CAS
126-18-1
分子式
C27H44O3
分子量
416.64
MOL 文件
126-18-1.mol
更新日期
2024/04/18 16:41:38
126-18-1 结构式
基本信息
中文别名
菝葜菝葜配質
菝葜配基
异菝葜皂甙
英文别名
Nsc93747SMILAGENIN
ESMILAGENIN
ISOSARSAPOGENIN
Smilax china L
ISOSARSAPOGENINE
ISOSARSASAPOGENIN
SMILAGENIN USP/EP/BP
(25r)-spirostan-3β-ol
(25R)-SPIROSTAN-3BETA-OL
所属类别
生物化工：中草药成分物理化学性质
熔点~185 °C
比旋光度D25 -69° (c = 0.5 in chloroform)
沸点474.91°C (rough estimate)
密度1.0362 (rough estimate)
折射率1.4700 (estimate)
储存条件-20°C储存
溶解度Ethanol: ≥ 10 mg/mL (24.00 mM); DMSO: < 1 mg/mL (insoluble or slightly soluble)
酸度系数(pKa)15.14±0.70(Predicted)
菝葜价格(试剂级)
| 报价日期 | 产品编号 | 产品名称 | CAS号 | 包装 | 价格 |
| 2024/01/25 | HY-106353 | 菝葜 Smilagenin | 126-18-1 | 5mg | 800元 |
| 2024/01/25 | HY-106353 | 菝葜 Smilagenin | 126-18-1 | 10mM * 1mLin DMSO | 880元 |
| 2024/01/25 | HY-106353 | 菝葜 Smilagenin | 126-18-1 | 10mg | 1200元 |
常见问题列表
生物活性
Smilagenin (SMI) 是一种脂溶性小分子甾体皂苷元，来自知母 Rhizoma anemarrhenae 和天竺葵 Radix asparagi，广泛用于慢性神经退行性疾病的研究。Smilagenin (SMI) 通过增加毒蕈碱受体亚型 1 (M1)-受体的的密度来改善老年大鼠的记忆。
Smilagenin (SMI) 通过刺激脑源性神经营养因子的基因表达减弱 Aβ (25-35) 诱导的神经变性，可用于 AD 的研究。靶点
|
Human Endogenous Metabolite
|
体外研究
Smilagenin (10 μM; 24 hours) increases SH-SY5Y cell survival compared with Aβ(25-35) intoxicated cells. Smilagenin (10 μM; 24 hours) increases neurotrophic factor (GDNF) and neurotrophic factor (BDNF) mRNA level by promoting CREB phosphorylation in 1-methyl-4-phenylpyridimium (MPP + ) treated SH-SY5Y cells.
Cell Viability Assay
| Cell Line: | SH-SY5Y cells |
| Concentration: | 10 μM |
| Incubation Time: | 24 hours |
| Result: | Elevated the SH-SY5Y cell viability. |
RT-PCR
| Cell Line: | SH-SY5Y cells |
| Concentration: | 10 μM |
| Incubation Time: | 24 hours |
| Result: | Increased GDNF and BDNF transcription. |
体内研究
Smilagenin (intragastric administration; 10 or 26 mg/kg, once daily; 60 days) prevents the impairment of dopaminergic neurons in chronic MPTP/probenecid-induced mouse model.
| Animal Model: | MPTP/probenecid-induced mouse model |
| Dosage: | 10 or 26 mg/kg |
| Administration: | Intragastric administration; 10 or 26 mg/kg; once daily; 60 days |
| Result: | Ameliorated locomotor ability of MPTP/probenecid-lesioned mice. |